Yes, I see where you are coming from with that. The clinical trials should be the really expensive part and the analysis should be at a lower cost.
There will be other expenses - and general non research expenses look like they are over $200k per quarter.
BIT will still need to create more cash moving forward so, it is prudent to have a CR soon. All companies do that and BIT will have to set itself up for the immediate future. CR is not a dirty word - just a management tool
Thanks for pointing that out.
Yes, I see where you are coming from with that. The clinical...
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.002(3.77%) |
Mkt cap ! $49.62M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.8¢ | 5.3¢ | $21.00K | 378.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 81011 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 62742 | 3 |
View Market Depth
| Last trade - 15.46pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.5¢ |
Change
0.002 ( 3.77 %) |
||||
| Open | High | Low | Volume | ||
| 5.3¢ | 5.8¢ | 5.3¢ | 205102 | ||
| Last updated 15.29pm 28/05/2024 ? | |||||
| BIT (ASX) Chart |